Atlas Trials

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

Clinical trial NCT03980041 · COMPLETED

Trial details

NCT number
NCT03980041
Sponsor
Infinity Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Bladder CancerUrothelial CarcinomaSolid TumorAdvanced Cancer
Start date
2019-09-25
Primary completion
2020-11-30
Enrollment
49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.